Siamab Therapeutics (formerly Sialix) has refocused on developing monoclonal antibodies to hinder tumor growth and advance cancer immunotherapy. The company targets tumor-associated carbohydrate antigens (TACAs), abnormal glycans on cancer cell surfaces, and says it has identified highly specific antibodies that can kill tumor cells and inhibit progression. Its technology was licensed from glycobiology researcher Ajit Varki at the University of California, San Diego, and Siamab maintains corporate headquarters in Cambridge while doing lab work in San Diego. With the latest funding the company is developing in vivo data for its first program and building an IND-enabling data package, with the aim of entering the clinic in the next couple of years. Financially, Siamab completed a $6 million Series B that began last year, with an additional $2 million tranche announced recently largely from angel investors.

Total raised

$2M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2014